VU6001966 是一种具有血脑屏障穿透性和选择性的 mGlu2 受体抑制剂,可阻断 mGlu2 受体活性,在炎症条件下抵消 LY379268 (MS-O73814) 介导的小胶质细胞血脑屏障保护作用及炎性细胞因子抑制作用,与 Scopolamine (MS-P46812) 联用时还可增强抗抑郁作用,因此可用于重度抑郁症的相关研究。
产品编号: MS-E84203 纯度: 99.89% CAS No.: 2009052-76-8 分子式: C17H15FN4O2 分子量: 326.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

VU6001966 是一种具有血脑屏障穿透性和选择性的 mGlu2 受体抑制剂,可阻断 mGlu2 受体活性,在炎症条件下抵消 LY379268 (MS-O73814) 介导的小胶质细胞血脑屏障保护作用及炎性细胞因子抑制作用,与 Scopolamine (MS-P46812) 联用时还可增强抗抑郁作用,因此可用于重度抑郁症的相关研究。

生物实验数据

生物活性 VU6001966 is a blood-brain barrier-penetrant and selective mGlu2 receptor inhibitor that blocks mGlu2 receptor activity, counteracts LY379268 (MS-O73814)-mediated microglial blood-brain barrier protection and inflammatory cytokine suppression under inflammatory conditions, and enhances antidepressant effects when combined with Scopolamine (MS-P46812), making it suitable for research related to major depressive disorder.
IC50 & Target mGluR3:>30 μM, mGluR2:78 nM
体外研究
(In Vitro)

VU6001966 (3 μM;24-36 小时) 不会干扰 LY379268 对 TNF-α&IFNγ (T&I) 诱导的血脑屏障功能受损所产生的保护作用;这些受保护的屏障功能指标包括:在 TY-10 人脑微血管内皮细胞单层培养体系中的通透性、TEER 值及紧密连接蛋白的定位;以及在 TY-10 人脑微血管内皮细胞与 hAST 人星形胶质细胞共培养体系中的通透性、TEER 值及 Claudin-5 的表达。
VU6001966 (3 μM;36 小时) 可显著减弱 LY379268 对 TY-10 人脑微血管内皮细胞+hAST 人星形胶质细胞+HMC3 人小胶质细胞三重共培养体系中,由 T&I 损伤引发的血脑屏障通透性异常及 claudin-5 表达下调的保护作用。
VU6001966 (3 μM;5 小时) 可显著逆转 LY379268 对 T&I 诱导的细胞因子/趋化因子表达的抗炎作用,并阻断 LY379268 诱导的 HMC3 人小胶质细胞单培养物中 BDNF 表达的上调。
VU6001966 可强效抑制 rmGlu2/TREx/Gα15-HEK 细胞中的 rmGlu2,其 IC50 为 78 nM;在浓度高达 30 μM 时,对 rmGlu3/TREx/Gα15-HEK 细胞中的 rmGlu3 无活性。
VU6001966 在浓度高达 30 μM 时也不会抑制 CYP3A4、CYP2D6 或 CYP2C9,但会抑制 CYP1A2,其 IC50 为 3.1 μM。

Real Time qPCR

Cell Line: human microglial (HMC3) monocultures
Concentration: 3 μM
Incubation Time: 5 h
Result: Significantly reversed the LY379268-induced reduction in T&I-increased IL-6, IL-1β, and CCL2 mRNA expression.
Significantly blocked the LY379268-induced increase in BDNF mRNA expression in resting microglia.
体内研究
(In Vivo)

VU6001966 (1-10 mg/kg;腹腔注射;每日一次;连续 4 天) 可呈剂量依赖性缓解小鼠应激诱导的快感缺失样及冷漠样行为。
VU6001966 (1 mg/kg;腹腔注射;每日 1 次;连续 4 天) 与 Scopolamine 联用可缓解小鼠中慢性不可预测温和应激 (UCMS) 诱导的快感缺失样及冷漠样行为,且对未受应激的动物无影响。
VU6001966 (1 mg/kg;腹腔注射;每日 1 次;连续 4 天) 与 Scopolamine 联合给药,可使 UCMS 暴露小鼠产生类抗抑郁效应,且该效应不会被 AMPA 受体拮抗作用阻断,同时不损伤小鼠的自主活动能力。
VU6001966 (1 mg/kg;腹腔注射;每日一次;连续 4 天) 与 Scopolamine 联合给药,会在 UCMS 暴露小鼠中产生依赖于 TrkB 受体激活的类抗抑郁作用,且不会损害自主活动能力。
VU6001966 (1 mg/kg;腹腔注射;每日一次;连续 4 天) 与 Scopolamine 联合给药可逆转 UCMS 诱导的小鼠前额叶皮层 TrkB 磷酸化缺陷。
VU6001966 (1 mg/kg;腹腔注射;每日一次;连续 4 天) 与 Scopolamine 联合给药无法显著逆转 UCMS 诱导的小鼠 mPFC 谷氨酸能传递或突触可塑性损伤。
VU6001966 (腹腔注射,1 mg/kg,每日 1 次,连续 4 天) 与 Scopolamine 联合给药,不会损伤未受应激或暴露于 UCMS 的小鼠的空间认知功能或非空间认知功能。
VU6001966 (1-10 mg/kg;腹腔注射;单次给药) 在大鼠强迫游泳试验中呈现剂量依赖性的类抗抑郁作用,其中 10 mg/kg 剂量可显著缩短不动时间,且不影响自发活动。
VU6001966 (3 mg/kg;腹腔注射;单次给药) 可显著增强大鼠强迫游泳试验中的类抗抑郁作用,当与 Scopolamine 联合给药时,可减少大鼠不动时间并增加攀爬行为。
VU6001966 (3 mg/kg;腹腔注射;单次给药) 可调节自由活动大鼠前额叶皮层的神经递质水平,升高血清素和多巴胺水平同时降低谷氨酸水平;当与 Scopolamine 联合给药时,它还能增强 Scopolamine 诱导的上述神经递质升高作用。

Animal Model: C57BL/6J (male, 6-7 weeks old, 23-25 g, unpredictable chronic mild stress model)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.p.; daily; 4 days
Result: Dose-dependently alleviated UCMS-induced depressive-like behaviors.
Significantly increased grooming time in the splash test (P = 0.0423) at 3 mg/kg compared to vehicle-treated UCMS mice.
Significantly increased grooming time (P < 0.0001) and sucrose preference (P < 0.0001) at 10 mg/kg compared to vehicle-treated UCMS mice.
Did not affect immobility time in the tail suspension test at 10 mg/kg.
Showed no significant effect on any measured behavioral parameter at 1 mg/kg.
Animal Model: C57BL/6J (male, 6-7 weeks old, 23-25 g, unpredictable chronic mild stress model)
Dosage: 1 mg/kg
Administration: i.p.; daily; 4 days
Result: Significantly reversed UCMS-induced reductions in grooming time in the splash test (P < 0.0001) and sucrose preference in the sucrose preference test (P = 0.0044) compared to vehicle-treated UCMS mice.
Had no effect in non-stressed mice.
Did not significantly affect immobility time in the tail suspension test in either UCMS or non-stressed mice.
Significantly increased grooming time in the splash test (P = 0.0019) and decreased immobility time in the tail suspension test (P = 0.0235) compared to vehicle-treated UCMS mice.
Did not significantly affect locomotor activity at any time point compared to vehicle-treated UCMS mice.
Significantly increased grooming time in the splash test (P = 0.0007) and decreased immobility time in the tail suspension test (P = 0.0039) compared to vehicle-treated UCMS mice.
Had no significant effect on sucrose preference in the sucrose preference test in UCMS mice.
Did not significantly affect locomotor activity at any time point compared to vehicle-treated UCMS mice.
Significantly reversed UCMS-induced reductions in the phospho-TrkB(Tyr816)/TrkB ratio in the PFC (P = 0.0492) compared to vehicle-treated UCMS mice.
Did not significantly affect peEF2/eEF2, pmTOR/mTOR, or BDNF levels in the PFC, nor any measured protein ratios or levels in the hippocampus.
Did not significantly reverse UCMS-induced increases in FP amplitude or UCMS-induced decreases in LTP amplitude in the mPFC, though a non-significant trend toward alleviating the FP amplitude increase was observed.
Did not significantly affect sEPSC frequency or amplitude in either UCMS or non-stressed mice.
Did not significantly affect moved object investigation time in the OLT or novel object investigation time in the NORT in either UCMS or non-stressed mice, indicating no impairment of spatial or non-spatial cognitive function.
Animal Model: Sprague-Dawley (male, 250-350 g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.p.; single dose
Result: Induced a dose-dependent reduction in immobility time in the forced swim test.
Produced a statistically significant decrease in immobility time at 10 mg/kg (P = 0.037 vs. vehicle).
Had no effect on immobility, climbing, or swimming times at 1 mg/kg and 3 mg/kg.
Did not alter spontaneous locomotor activity at 3 mg/kg.
Animal Model: Sprague-Dawley (male, 250-350 g)
Dosage: 3 mg/kg
Administration: i.p.; single dose
Result: Produced a significant decrease in immobility time (F(1,22) = 4.35, P = 0.049) compared to individual treatments or vehicle.
Produced a significant increase in climbing time (F(1, 26) = 11.00, P = 0.003) compared to individual treatments or vehicle.
Animal Model: Sprague-Dawley (male, 250-350 g)
Dosage: 3 mg/kg
Administration: i.p.; single dose
Result: Elevated extracellular serotonin levels to approximately 300% of baseline, dopamine levels to approximately 200% of baseline, and decreased extracellular glutamate levels when administered alone.
Had no effect on GABA levels when administered alone.
Elevated serotonin levels to approximately 400% of baseline, dopamine levels to approximately 400% of baseline, glutamate levels to approximately 220% of baseline when coadministered with Scopolamine 0.3 mg/kg.
Had no significant effect on GABA levels compared to control when coadministered with Scopolamine 0.3 mg/kg.
性状 固体
颜色 White to off-white

化学信息

分子量 326.33
分子式 C17H15FN4O2
CAS No. 2009052-76-8

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 10 mg/mL (30.64 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0644 mL15.3219 mL30.6438 mL76.6096 mL
5 mM0.6129 mL3.0644 mL6.1288 mL15.3219 mL
10 mM0.3064 mL1.5322 mL3.0644 mL7.6610 mL
15 mM0.2043 mL1.0215 mL2.0429 mL5.1073 mL
20 mM0.1532 mL0.7661 mL1.5322 mL3.8305 mL
25 mM0.1226 mL0.6129 mL1.2258 mL3.0644 mL
30 mM0.1021 mL0.5107 mL1.0215 mL2.5537 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础